Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) has been given an average rating of "Buy" by the seven ratings firms that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $8.00.

A number of research firms have recently issued reports on QNCX. Oppenheimer began coverage on shares of Quince Therapeutics in a research note on Monday, March 24th. They set an "outperform" rating and a $10.00 target price for the company. D. Boral Capital restated a "buy" rating and set a $4.00 target price on shares of Quince Therapeutics in a research note on Friday, June 13th. Finally, Wall Street Zen cut shares of Quince Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.

Hedge Funds Weigh In On Quince Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Ieq Capital LLC bought a new position in Quince Therapeutics during the first quarter worth about $1,073,000. Virtu Financial LLC increased its position in Quince Therapeutics by 48.4% during the first quarter. Virtu Financial LLC now owns 43,332 shares of the company's stock worth $58,000 after acquiring an additional 14,128 shares during the period. Intellectus Partners LLC bought a new position in Quince Therapeutics during the first quarter worth about $71,000. Two Sigma Investments LP bought a new position in Quince Therapeutics during the fourth quarter worth about $57,000. Finally, Shay Capital LLC increased its position in Quince Therapeutics by 60.8% during the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company's stock worth $518,000 after acquiring an additional 104,616 shares during the period. 30.75% of the stock is owned by institutional investors.

Quince Therapeutics Stock Performance

Shares of NASDAQ QNCX traded up $0.05 during mid-day trading on Thursday, reaching $1.55. 137,969 shares of the company were exchanged, compared to its average volume of 305,019. The company's 50-day simple moving average is $1.14 and its 200-day simple moving average is $1.38. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $70.48 million, a P/E ratio of -1.12 and a beta of 0.80. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). As a group, research analysts predict that Quince Therapeutics will post -1.21 earnings per share for the current year.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.